[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564764":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":50,"centralContacts":54,"locations":55,"responsibleParty":69,"collaborators":54,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":54,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":54,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":54,"overallStatus":91,"whyStopped":54,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Opevesostat Period 1","EXPERIMENTAL","On Day 1 a single dose of opevesostat will be administered under fasting conditions and a single dose of hormone replacement therapy (HRT) (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after opevesostat dosing.",[13,14,15],"Drug: Opevesostat","Drug: Prednisone","Drug: Fludrocortisone acetate",{"label":17,"type":10,"description":18,"interventionNames":19},"Opevesostat Period 2","There will be a washout of at least 5 days between opevesostat dosing in Period 1 and the first carbamazepine dosing in Period 2. In Period 2, carbamazepine will be administered twice daily (BID) for 17 consecutive days with a single dose of opevesostat coadministered on the morning of Day 14 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions on Day 14, approximately 4.5 hours after opevesostat and\u002For carbamazepine dosing.",[13,14,15,20],"Drug: Carbamazepine",[22,30,38,44],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Opevesostat","Administered via oral tablet per dosing regimen.",[9,17],[28,29],"MK-5684","ODM-208",{"type":23,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Prednisone","Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.",[9,17],[35,36,37],"RAYOS®","STERAPRED®","DELTASONE®",{"type":23,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Fludrocortisone acetate","Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.",[9,17],[43],"FLORINEF®",{"type":23,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Carbamazepine","Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).",[17],[49],"TEGRETOL®",[51],{"name":52,"affiliation":5,"role":53},"Medical Director","STUDY_DIRECTOR",null,[56],{"facility":57,"status":54,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":54},"Celerion ( Site 0001)","Tempe","Arizona","85283","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-111.90931,33.41477,{"lat":67,"lon":66},{"type":70,"investigatorFullName":54,"investigatorTitle":54,"investigatorAffiliation":54,"oldNameTitle":54,"oldOrganization":54},"SPONSOR","100564764","phase-1-a-drug-drug-interaction-study-of-carbamazepine-and-opevesostat-mk-5684-in-healthy-adult-male-participants-mk-5684-012-100564764",false,"NCT06633419","A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Carbamazepine on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting\n* Body mass index (BMI) ≥18.0 and ≤32.0 kg\u002Fm\\^2\n* Able to swallow multiple tablets\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* History or presence of any of the following:\n\n  * Adrenal insufficiency\n  * Hepatic or renal impairment\n  * Gallstones, hepatitis disease, or hepatic porphyrias\n  * Psychosis\n  * Clinically significant hypotension, cardiac arrhythmia, cardiac conduction abnormalities, or recurrent unexplained syncopal events\n  * Second- or third-degree atrioventricular heart block\n  * Clinically significant sick sinus syndrome\n  * Recurrent seizures, increased risk for seizures, or myasthenia gravis\n  * Clinically significant hematologic disorders\u002Fblood dyscrasias, including adverse hematologic reactions to any drugs or experimental therapies\n  * Any systemic fungal infection\n  * Chronic infection\n  * Glaucoma\n  * Hypothyroidism\n  * Unexplained electrolyte abnormalities, current hyponatremia, diuretic use, or syndrome of inappropriate antidiuretic hormone secretion (siADH)\n  * Severe dermatologic reaction\n  * Stomach ulcer\n* Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)\n* History of cancer (malignancy)\n* Unable to refrain from or anticipates the use of: Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing",true,"MALE","18 Years","55 Years",{"count":83,"type":84},14,"ACTUAL","INTERVENTIONAL",[87],"PHASE1","Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer.\n\nThe purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called carbamazepine.",[90],"Healthy","COMPLETED","2025-05-22",{"date":94,"type":84},"2025-05-25",{"date":96,"type":84},"2024-12-18",{"date":98,"type":84},"2025-05-13",{"name":5,"class":6},1]